Clinical trials
Gemcitabine clinical trials
Below are recruiting gemcitabine clinical trials, each written for real people, not researchers. We’re tracking 373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07043270RecruitingPhase 2
Alternating chemo regimens for borderline resectable pancreatic cancer
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
Lebanon, New HampshireAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07079228RecruitingPhase 3
Comparing a new drug with chemo for pancreatic cancer
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
BeijingAges 18–75 - NCT07081022RecruitingPhase 2
Study of JS203 combination therapy for B-cell lymphoma
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Fort Smith, ArkansasAges 18 years+ - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07124936RecruitingPhase 1/Phase 2
Study of new drug plus standard care for large B-cell lymphoma
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07131514RecruitingPhase 2
Combination therapy for pancreatic cancer before and after surgery
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
ShanghaiAges 18–80 - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07235007Recruiting
New treatment for bile duct cancer with heat, immunotherapy, and chemo
This trial tests a combination of heat therapy inside the bile duct (endobiliary RFA) with immunotherapy (durvalumab) and chemotherapy (gemcitabine and cisplatin) for people with unresectable extrahepatic cholangiocarcinoma. The goal is to see if adding the heat treatment improves outcomes.
AichiAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07325539RecruitingPhase 2
Radiation and immunotherapy with chemo for nose and throat cancer
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–65 - NCT07393542RecruitingPhase 3
New Drug Combo for Advanced Bladder Cancer
This trial tests a new drug combination (SHR-A2102 plus an immunotherapy) for people with advanced bladder cancer who have not yet had any treatment. The goal is to see if the combination helps shrink tumors and slows the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT07119996RecruitingPhase 1
Vitamin B3 to boost immunotherapy for bladder cancer
This trial tests whether taking vitamin B3 can help immunotherapy work better for people with bladder cancer. It’s for patients who have a certain type of bladder cancer and have had a recent infection that needed antibiotics.
Guangzhou, GuangdongAges 18 years+ - NCT07398339RecruitingPhase 2
Photodynamic therapy for bile duct cancer
This trial tests a light-activated drug called cosiporfin sodium for people with advanced bile duct cancer that cannot be surgically removed. The treatment targets tumors in the bile ducts and may help shrink them.
Shanghai, Pudong New AreaAges 18 years+ - NCT07418749RecruitingPhase 3
Testing a new drug for advanced cervical cancer after standard treatments
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Guangzhou, GuangdongAges 18 years+ - NCT07433673RecruitingPhase 2
Gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab for locally advanced bile duct cancer
This trial tests a combination of four drugs to see if they shrink locally advanced bile duct or gallbladder cancer that cannot be removed surgically. It is for people who have not had prior treatment for this cancer.
New York, New YorkAges 18 years+ - NCT07447076RecruitingPhase 2
New treatments for recurrent ATRT brain tumor
This trial tests new treatments for children and young adults whose ATRT brain tumor has come back or grown. It aims to find if these therapies can help control the tumor.
San Francisco, CaliforniaAges 1–39 - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Gemcitabine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gemcitabine?
- Yes. Clin2 currently lists 373 recruiting gemcitabine studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gemcitabine trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gemcitabine trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.